Ignite Creation Date:
2024-05-06 @ 8:09 AM
Last Modification Date:
2024-10-26 @ 11:56 AM
Study NCT ID:
NCT02679170
Status:
COMPLETED
Last Update Posted:
2022-06-10
First Post:
2016-02-05
Brief Title:
Study to IDEntify Patients With AdvancedMetastatic Non Small Cell Lung Cancer NSCLC and ALK and ROS1 Translocation and to Establish Their Therapeutic Management IDEALKROS
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Observational Study to IDEntify Patients With AdvancedMetastatic NSCLC and ALK and ROS1 Translocation and to Establish Their Therapeutic Management IDEALKROS
Status:
COMPLETED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Prospective observational study to IDEntify patients with advancedmetastatic NSCLC and ALK and ROS1 translocation and to establish their therapeutic management IDEALKROS
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| IDEALKROS | OTHER | None | None |
| IDEALK | OTHER | Alias Study Number | None |